Omeros (OMER) Downgraded by ValuEngine

Omeros (NASDAQ:OMER) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

A number of other equities analysts also recently weighed in on the company. Cowen downgraded Omeros from an “outperform” rating to a “market perform” rating in a report on Thursday, November 2nd. Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. Maxim Group set a $24.00 target price on Omeros and gave the company a “buy” rating in a report on Friday, October 20th. HC Wainwright started coverage on Omeros in a report on Wednesday, November 8th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $47.00 target price on shares of Omeros in a report on Tuesday, November 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $30.38.

Shares of Omeros (NASDAQ:OMER) traded down $2.40 on Wednesday, hitting $11.25. The stock had a trading volume of 5,700,000 shares, compared to its average volume of 730,690. The firm has a market cap of $540.04, a P/E ratio of -8.72 and a beta of 3.30. Omeros has a one year low of $10.51 and a one year high of $27.09. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99.

A number of large investors have recently added to or reduced their stakes in the stock. Teachers Advisors LLC increased its holdings in Omeros by 7.1% in the fourth quarter. Teachers Advisors LLC now owns 80,820 shares of the biopharmaceutical company’s stock worth $1,570,000 after buying an additional 5,355 shares during the last quarter. Ellington Management Group LLC acquired a new position in Omeros in the fourth quarter worth approximately $301,000. Deutsche Bank AG increased its holdings in Omeros by 120.8% in the fourth quarter. Deutsche Bank AG now owns 105,909 shares of the biopharmaceutical company’s stock worth $2,057,000 after buying an additional 57,945 shares during the last quarter. Cypress Capital Group acquired a new position in Omeros in the fourth quarter worth approximately $194,000. Finally, USA Financial Portformulas Corp acquired a new position in Omeros in the fourth quarter worth approximately $451,000. Hedge funds and other institutional investors own 50.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Omeros (OMER) Downgraded by ValuEngine” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/omeros-omer-downgraded-by-valuengine.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply